remain neutral rate share find littl quibbl quarter
report broad-bas albeit modest revenu beat non-gaap ep
beat help along lower spend ep guidanc rais
manag specif highlight willing rais ep guidanc face eu
loe humira later year notic revenu guidanc rather
actual came slightli continu worri consensu fulli
factor extent ex-u humira pressur us pressur co-pay
accumul program humira continu prefer sidelin
solid beat total revenu beat consensu pjc
ep ahead consensu pjc driven
humira beat revenu vs consensu pjc hcv franchis
revenu beat consensu pjc imbruvica revenu
beat consensu pjc expens disciplin also help ep beat
 spend consensu expect
ep guidanc rais revenu guidanc quietli lower ep guidanc
increas improv margin
outlook oper margin guid vs prior guidanc total
revenu year actual guid slightli expect approach
vs prior guidanc approach gener function
currenc dynam favor impact guid vs previous
product-specif guidanc either maintain slightli increas still think
leav door open hand wring happen upon ex-u biosimilar humira
launch later year
key fear remain continu see risk/reward name skew
toward risk survey data indic pressur humira loe
europ could anticip coupl concern co-pay
accumul may weigh us humira revenu view backfil catalyst
come quarter larg price share continu prefer sidelin
lower target adjust model incorpor updat
guidanc price target move deriv
appli multipl previous ep discount back
think lower multipl approach humira ex-u loe appropri
commerci regulatori clinic ip risk associ market pipelin product
fulli integr biopharmaceut compani
ep discount back
year
debt total capit
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
page
good sold
product sale
total revenu
sell gener administr
total revenu
statement oper
dollar except per share data
provis incom tax tax benefit
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
page
dollar except per share data
row revenu
elotuzumab revenu
total ww elotuzumab revenu
row profit share
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
